9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NMTR vs. CDT, GLTO, DRMA, SPRB, EVAX, ORGS, PPBT, JAGX, SHPH, and CNSPShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include CDT Equity (CDT), Galecto (GLTO), Dermata Therapeutics (DRMA), Spruce Biosciences (SPRB), Evaxion A/S (EVAX), Orgenesis (ORGS), Purple Biotech (PPBT), Jaguar Animal Health (JAGX), Shuttle Pharmaceuticals (SHPH), and CNS Pharmaceuticals (CNSP). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Its Competitors CDT Equity Galecto Dermata Therapeutics Spruce Biosciences Evaxion A/S Orgenesis Purple Biotech Jaguar Animal Health Shuttle Pharmaceuticals CNS Pharmaceuticals 9 Meters Biopharma (NASDAQ:NMTR) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends. Do institutionals & insiders have more ownership in NMTR or CDT? 22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by insiders. Comparatively, 7.7% of CDT Equity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor NMTR or CDT? In the previous week, CDT Equity had 4 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for 9 Meters Biopharma. CDT Equity's average media sentiment score of 0.20 beat 9 Meters Biopharma's score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media. Company Overall Sentiment 9 Meters Biopharma Neutral CDT Equity Neutral Which has higher valuation & earnings, NMTR or CDT? CDT Equity is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/ACDT EquityN/AN/A-$17.80M-$435.000.00 Is NMTR or CDT more profitable? CDT Equity's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets 9 Meters BiopharmaN/A -584.97% -159.45% CDT Equity N/A N/A -350.23% Which has more volatility & risk, NMTR or CDT? 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, CDT Equity has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. SummaryCDT Equity beats 9 Meters Biopharma on 6 of the 10 factors compared between the two stocks. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$224.50M$5.76B$9.91BDividend YieldN/A3.78%6.71%4.52%P/E Ratio0.0043.0175.5426.08Price / SalesN/A5,200.75480.4288.28Price / CashN/A13.1936.9659.01Price / BookN/A87.2111.446.09Net Income-$43.77M-$90.99M$3.28B$266.14M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A0.0020CDTCDT Equity0.1018 of 5 stars$1.33flatN/A-99.4%$4.07MN/A0.003News CoverageShort Interest ↑GLTOGalecto3.5797 of 5 stars$3.00-5.7%$10.00+233.3%-74.1%$3.96MN/A-0.2340Positive NewsShort Interest ↓DRMADermata Therapeutics2.1019 of 5 stars$5.78+0.7%$10.00+73.0%-63.2%$3.94MN/A-0.358Short Interest ↑SPRBSpruce Biosciences1.6226 of 5 stars$7.00-6.7%$131.25+1,775.0%-73.9%$3.93M$4.91M-7.4520News CoverageGap DownEVAXEvaxion A/S1.6975 of 5 stars$2.78+1.1%$10.00+259.7%-82.6%$3.89M$3.34M-2.1160ORGSOrgenesisN/A$0.80-20.0%N/AN/A$3.84M$662K0.00150Gap DownPPBTPurple Biotech2.7717 of 5 stars$1.42-28.6%$33.00+2,223.9%N/A$3.68MN/A-3.3820News CoverageShort Interest ↓Gap DownHigh Trading VolumeJAGXJaguar Animal Health2.4921 of 5 stars$1.67+2.5%$60.00+3,492.8%-93.7%$3.62M$11.69M0.0050Positive NewsShort Interest ↓Gap UpSHPHShuttle Pharmaceuticals0.7804 of 5 stars$3.38+2.4%N/A-93.8%$3.62MN/A-0.815News CoveragePositive NewsGap UpCNSPCNS Pharmaceuticals1.6469 of 5 stars$6.26+1.0%$300.00+4,691.6%-93.1%$3.57MN/A0.005Analyst Downgrade Related Companies and Tools Related Companies CDT Alternatives GLTO Alternatives DRMA Alternatives SPRB Alternatives EVAX Alternatives ORGS Alternatives PPBT Alternatives JAGX Alternatives SHPH Alternatives CNSP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMTR) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMTR Stock Alerts